Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study

Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study

Aim. To evaluate the effectiveness and safety of Extimia® BIOCAD (international non-proprietary name: empegfilgrastim) to reduce the incidence and duration of neutropenia, the incidence of febrile neutropenia (FN) and infections associated with FN in patients with lymphoproliferative diseases receiv...

Full description

Bibliographic Details
Main Authors: Ekaterina S. Nesterova, Aleksandra F. Saydullaeva, Dmitry G. Sherstnev, Tatiana V. Shelekhova, Tatiana Yu. Klitochenko, Gulnara N. Khusainova, Irina B. Lysenko, Irina S. Lyalina, Marina V. Demchenkova, Svetlana A. Orlova, Andrei V. Proydakov, Мadina V. Betrozova, Natalia V. Fadeeva, Alina A. Gofman, Yana M. Marchenko, Sergey V. Voloshin, Elena A. Pashneva, Vladislav O. Sarzhevskiy, Alina R. Babicheva, Irina B. Bondareva, Natalia N. Glonina, Damir G. Ishchanov, Irina V. Poddubnaya
Format: Article
Language:Russian
Published: IP Habib O.N. 2023-12-01
Series:Современная онкология
Subjects:
non-hodgkin's lymphoma
empegfilgrastim
pegylated colony-stimulating factor
clinical practice
prevention of neutropenia
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/627191/142914

Internet

https://modernonco.orscience.ru/1815-1434/article/viewFile/627191/142914

Similar Items